API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/06/04/2893001/0/en/Apollomics-Announces-Vebreltinib-Data-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/25/2869647/0/en/Apollomics-Announces-Approval-of-Vebreltinib-in-China-as-a-First-in-Class-Treatment-for-Gliomas-with-MET-Fusion-Gene.html
https://www.globenewswire.com/news-release/2024/04/10/2860624/0/en/Apollomics-Presents-Vebreltinib-Data-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/02/2855887/0/en/Apollomics-Announces-Poster-Presentations-of-Vebreltinib-Data-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/12/04/2789889/0/en/Apollomics-Presents-Interim-Data-from-Two-Ongoing-Phase-2-Clinical-Trials-with-Vebreltinib-in-NSCLC-Patients-with-MetExon14-Skipping-Mutation.html
https://www.globenewswire.com//news-release/2023/11/16/2781844/0/en/Apollomics-Announces-the-First-Approval-of-Vebreltinib-for-MET-Exon-14-Skip-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com//news-release/2023/10/31/2770195/0/en/Apollomics-Announces-Two-New-Cohorts-in-Global-Phase-2-SPARTA-Study-of-Vebreltinib-in-Non-Small-Cell-Lung-Cancer-and-Other-Solid-Tumors-with-MET-Dysregulation.html
https://www.globenewswire.com//news-release/2023/10/23/2764733/0/en/Apollomics-Announces-Efficacy-of-Vebreltinib-in-NSCLC-Patients-with-MetEx14-Skipping-Mutation-Achieving-an-Overall-Response-Rate-ORR-of-75.html